Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years old, who must understand and voluntarily sign an Informed Consent.~* Patients must have documented diagnosis of Multiple Myeloma and have measurable disease.~* Patients must have undergone prior treatment with ≥ 2 treatments lines, of anti-myeloma therapy.~* Patients must have either refractory or relapsed and refractory disease.~* Patients must have received at least 2 consecutive cycles of prior treatment that include lenalidomide and bortezomib, either alone or in combination regimens.~* Patients must have received adequate alkylator therapy~Exclusion Criteria:~* Prior history of malignancies, other than Multiple Myeloma.~* Previous therapy with Pomalidomide, hypersensitivity to thalidomide and lenalidomide or dexamethasone.~* Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant.~* Patients who are planning for or who are eligible for stem cell transplant.~* Patients who received major surgery and any anti-myeloma drug therapy within the last 14 days of starting study treatment.~* Patients with a current disease that can interfere with protocol procedures or study treatment.~* Patients unable or unwilling to undergo antithrombotic prophylactic treatment.~* Pregnant or breastfeeding females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide plus Dexamethasone (Type: EXPERIMENTAL): Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).